Vancouver's Angiotech Pharmaceuticals Inc. (TSX:ANP; Nasdaq:ANPI) has won a patent court case in the U.K. recognizing the company's patent covering its stent projects.
The U.K. House of Lords overturned lower U.K. court decisions, which had ruled that Angiotech's paclitaxel stent patent was invalid. This occurred even though Angiotech had received a patent for the same technology from the European Patent Office, which was successfully defended in the Dutch courts.
The House of Lords' decision in favour of Angiotech could bring greater uniformity to the interpretation of the European Patent Convention among the national courts in Europe and the European Patent Office.
Angiotech's share price range during the past week: between $2.55 and $2.93; 52-week high: $7.89; 52-week low: $1.50.